With 166.16 million shares changed hands, the volume of the stock remained heavier than its average volume of 3.89 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.06 whereas the lowest price it dropped to was $1.34. The 52-week range on KTTA shows that it touched its highest point at $3.85 and its lowest point at $0.28 during that stretch. It currently has a 1-year price target of $40.00. Beta for the stock currently stands at 0.24.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of KTTA was up-trending over the past week, with a rise of 254.13%, but this was up by 103.18% over a month. Three-month performance surged to 81.89% while six-month performance rose 51.55%. The stock lost -53.33% in the past year, while it has lost -51.80% so far this year.
Float and Shares Shorts:
At present, 7.44 million KTTA shares are outstanding with a float of 6.97 million shares on hand for trading. On 2025-11-14, short shares totaled 23343.0, which was 31.0 higher than short shares on 1760486400. In addition to Dr. Lawrence Steinman BA, M.D., Ph.D. as the firm’s Co-Founder, MD & Executive Chairman, Dr. Tiago Reis Marques M.D., Ph.D. serves as its CEO & Director.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-09-30, KTTA reported revenue of $0.0 and operating income of -$3110055.0. The EBITDA in the recently reported quarter was -$2949083.0 and diluted EPS was -$0.41.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. The surprise factor in the prior quarter was -$3.4.
